Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients

Q Medicine

Clinical Lipidology Pub Date : 2015-06-01 DOI:10.2217/clp.15.15

Min Wang, Shuiping Zhao, Ming-yue Tan, F. Huang

引用次数: 4

Abstract

Abstract Aims: Double-dose statin regimen achieves merely 6% of decrease in serum LDL cholesterol (LDL-C) levels, whereas the risk of side effects increased largely. Methods: In order to evaluate the lipid lowering effects and safety of combined therapy with Xuezhikang (XZK) and low-dose rosuvastatin, we recruited 30 patients to randomly divide into two groups, and then received combined therapy with XZK at 1.2 g/day and rosuvastatin at 5 mg/day or rosuvastatin at 10 mg/day, respectively. After 8 weeks, the subjects in the two groups cross-changed their treatments for the second period (8 weeks). Results: Compared with rosuvastatin alone, the combined therapy induced a significant decrease in LDL-C, total cholesterol and triglyceride with no serious adverse events, and exerted a slight effect on PCSK9 level. Discussion: The results suggest that combined therapy is a first-line therapeutic strategy for dyslipidemia patients.

查看原文本刊更多论文

血脂康联合小剂量瑞舒伐他汀治疗血脂异常是一种安全有效的治疗策略

目的:双剂量他汀方案仅能降低血清LDL- c (LDL- c)水平的6%，而副作用的风险却大大增加。方法:为评价血脂康与小剂量瑞舒伐他汀联合治疗的降脂效果及安全性，我们招募30例患者，随机分为两组，分别采用血脂康1.2 g/d、瑞舒伐他汀5 mg/d或瑞舒伐他汀10 mg/d联合治疗。8周后，两组受试者进行第二期治疗(8周)。结果:与单用瑞舒伐他汀相比，联合用药可显著降低LDL-C、总胆固醇和甘油三酯，无严重不良事件发生，对PCSK9水平影响较小。讨论:结果表明，联合治疗是血脂异常患者的一线治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.